The global market continues to expand, and Chinese manufacturers are accelerating their overseas expansion

According to the 2025 market report, the global insulin pen market has reached a size of RMB 35.38 billion and has maintained steady growth. Novo Nordisk, Eli Lilly, and Sanofi occupy the majority share.
Meanwhile, Chinese medical enterprises such as Pu'an Medical have risen to second place in the global insulin pen needle market, with a market share of 11.78%, and achieved a 23.69% market share in the European market, reflecting the competitiveness of domestic precision manufacturing in the international market.